Event-Driven Stocks

Immix Biopharma, Inc.

IMMXNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs3 good1 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$20.0M
Operating income−$30.0M−$22.7M−$16.1M−$8.2M−$1.4M−$453,852
Net income−$29.4M−$21.6M−$15.4M−$8.2M−$24.4M−$1.1M
Total assets$104.8M$22.9M$19.9M$14.9M$18.2M$539,597
Total liabilities$11.0M$9.7M$3.7M$1.7M$202,039$5.3M
Equity$93.8M$13.3M$16.4M$13.2M$18.0M−$4.7M
EPS (diluted)$-0.89$-0.76$-0.89$-0.59$-6.64
Shares out.27.7M26.4M13.9M13.9M13.2M3.4M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
Net margin
Return on equity
−31.4%
Return on assets
−28.1%
Return on capital (ROCE)
−31.6%
Liabilities / assets
10.5%
Debt / equity
0.12×
Book value / share
$3.38
Revenue growth (YoY)
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
9.45safe
Accruals / assets
5.3%clean
Piotroski F-Score
4/7mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
50
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

1 warning3 good
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20263.2M4.2+6.6%
Apr 30, 20263.0M4.4+1.9%
Apr 15, 20263.0M4.9-4.9%
Mar 31, 20263.1M3.0+3.9%
Mar 13, 20263.0M4.6+1.0%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗
  • 8-KMay 29, 2026
  • 4May 29, 2026
  • 4May 29, 2026
  • 4May 29, 2026
  • 4May 29, 2026
  • 4May 29, 2026
  • 4May 29, 2026
  • 4May 29, 2026
  • 4May 29, 2026
  • 4May 29, 2026
  • 8-KMay 21, 2026
  • 424B5May 21, 2026
  • FWPMay 21, 2026
  • 8-KMay 21, 2026
  • SCHEDULE 13G/AMay 15, 2026

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.